The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Powell, Arfon; Horgan, Paul G.; Edwards, Joanne

doi:10.1007/s00432-012-1192-4

Cited by 20 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[12][13][14] Accordingly, expression status of HLA class I molecules on tumor cells may influence prognosis, and several clinical studies showed that downregulation or low expression of HLA class I antigens was associated with a poor prognosis in a variety of malignant tumors, including NSCLC. 17,[34][35][36] PD-L1, expressing on tumor cells, also plays an important role in immune evasion at the final step by inhibiting activated CTLs. Accordingly, tumor cells with reduced HLA class I expression may evade immune attack regardless of PD-L1 expression on tumor cells, which may account for the lack of prognostic impact of PD-L1 status in tumors with reduced HLA class I expression found in the present study.…”

Section: Discussionmentioning

confidence: 99%

Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung

Hirai

Yoneda

Shimajiri

et al. 2018

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung

Hirai

Yoneda

Shimajiri

et al. 2018

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

“…The tissue sections were stained according to the previously described protocol [ 9 ]. Sections were incubated at room temperature over night with mouse monoclonal antibodies HCA2 and HC10 (anti-HLA-A and anti-HLAB/C, respectively) [ 9 , 23 ] for the detection of classical HLA class I on the tumor cell surface. Non-classical HLA class I staining was performed using mouse monoclonal antibodies against HLA-E (MEM-E/02 Clone (sc-51621, Santa Cruz biotechnology, Dallas, Texas) and HLA-G (4H84 Clone (sc-21799, Santa Cruz Biotechnology, Dallas, Texas) [ 8 ].…”

Section: Methodsmentioning

confidence: 99%

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis

Engels

Charehbili

Velde

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

Evidence exists for an immunomodulatory effect of endocrine therapy in hormone receptor-positive (HR+ve) breast cancer (BC). Therefore, the aim of this study was to define the prognostic and predictive value of tumor immune markers and the tumor immune profile in HR+ve BC, treated with different endocrine treatment regimens. 2,596 Dutch TEAM patients were treated with 5 years of adjuvant hormonal treatment, randomly assigned to different regimens: 5 years of exemestane or sequential treatment (2.5 years of tamoxifen–2.5 years of exemestane). Immunohistochemistry was performed for HLA class I, HLA-E, HLA-G, and FoxP3. Tumor immune subtypes (IS) (low, intermediate & high immune susceptible) were determined by the effect size of mono-immune markers on relapse rate. Patients on sequential treatment with high level of tumor-infiltrating FoxP3+ cells had significant (p = 0.019, HR 0.729, 95 % CI 0.560–0.949) better OS. Significant interaction for endocrine treatment and FoxP3+ presence was seen (OS p < 0.001). Tumor IS were only of prognostic value for the sequentially endocrine-treated patients (RFP: p = 0.035, HR intermediate IS 1.420, 95 % CI 0.878–2.297; HR low IS 1.657, 95 % CI 1.131–2.428; BCSS: p = 0.002, HR intermediate IS 2.486, 95 % CI 1.375–4.495; HR low IS 2.422, 95 % CI 1.439–4.076; and OS: p = 0.005, HR intermediate IS 1.509, 95 % CI 0.950–2.395; HR low IS 1.848, 95 % CI 1.277–2.675). Tregs and the tumor IS presented in this study harbor prognostic value for sequentially endocrine-treated HR+ve postmenopausal BC patients, but not for solely exemestane-treated patients. Therefore, these markers could be used as a clinical risk stratification tool to guide adjuvant treatment in this BC population.Electronic supplementary materialThe online version of this article (doi:10.1007/s10549-015-3269-7) contains supplementary material, which is available to authorized users.

show abstract

“…Several recent studies have reported that both the TME, including the TILs, macrophages, and immune-checkpoint molecules, and clinicopathologic features influence cancer prognosis. [6][7][8][9][10] In CRC, a high number of TILs are associated with better prognosis, 6,7 and the expression of some immune-checkpoint molecules can be useful prognostic biomarkers. 8,9,[11][12][13] However, it remains unclear whether immunity differs according to the tumor location and which cells or molecules are involved in cancer prognosis.…”

Section: Introductionmentioning

confidence: 99%

Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right‐sided and left‐sided colorectal cancer

et al. 2020

View full text Add to dashboard Cite

Tumor location and immunity play important roles in the progression of colorectal cancer (CRC). This study aimed to investigate the differences in the immunosurveillance pattern between right‐ and left‐sided CRC and analyze their association with clinicopathologic features, including mismatch repair (MMR) status. We included surgically resected stage II/III CRC cases and evaluated the immunohistochemical findings of HLA class I, HLA class II, programmed cell death‐ligand 1 (PD‐L1), PD‐1, CTLA‐4, CD3, CD4, CD8, TIA‐1, T‐bet, GATA3, RORγT, Foxp3, and CD163. A total of 117 patients were included in the analyses; of these, 30 and 87 had right‐ and left‐sided cancer, respectively. Tumor immunity varied according to the tumor location in the overall cohort. Analysis of the tumors excluding those with DNA mismatch repair (MMR) deficiency also revealed that tumor immunity differed according to the tumor location. In right‐sided colon cancer (CC), high expression of Foxp3 (P = .0055) and TIA‐1 (P = .0396) were associated with significantly better disease‐free survival (DFS). High CD8 (P = .0808) and CD3 (P = .0863) expression tended to have better DFS. Furthermore, in left‐sided CRC, only high PD‐L1 expression in the stroma (P = .0426) was associated with better DFS. In multivariate analysis, high Foxp3 expression in right‐sided CC was an independent prognostic factor for DFS (hazard ratio, 7.6445; 95% confidence interval, 1.2091‐150.35; P = .0284). In conclusion, the immunosurveillance pattern differs between right‐ and left‐sided CRC, even after adjusting for MMR deficiency.

show abstract

The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Cited by 20 publications

References 38 publications

Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung

Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis

Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right‐sided and left‐sided colorectal cancer

Contact Info

Product

Resources

About